compound 27 [PMID: 32551645]   Click here for help

GtoPdb Ligand ID: 11112

Compound class: Synthetic organic
Comment: Compound 27 was designed to offer improved clinical potential as a utrophin modulator than either ezutromid (failed at Phase 2) or SMT022357 (terminated at preclinical) [1]. This entry shows the compound without specified stereochemistry, to represent the racemic mixture. (+)-27 is slightly more active than (-)-27 or the racemate in vitro.

Clinical rationale: Up-regulation of utrophin (UTRN; P46939) as being investigated as a disease-modifying approach for Duchenne muscular dystrophy (DMD). In the mdx mouse DMD model, increased levels of utrophin effectively acts as a substitute for the dystrophin (DMD; P11532) that is missing in DMD [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 0
Rotatable bonds 4
Topological polar surface area 62.14
Molecular weight 319.08
XLogP 3.37
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCP(=O)(c1ccc2c(c1)nc(o2)c1ccc(cc1)F)OC
Isomeric SMILES CCP(=O)(c1ccc2c(c1)nc(o2)c1ccc(cc1)F)OC
InChI InChI=1S/C16H15FNO3P/c1-3-22(19,20-2)13-8-9-15-14(10-13)18-16(21-15)11-4-6-12(17)7-5-11/h4-10H,3H2,1-2H3
InChI Key MNCZMYLRBLYUPR-UHFFFAOYSA-N
References
1. Babbs A, Berg A, Chatzopoulou M, Davies KE, Davies SG, Edwards B, Elsey DJ, Emer E, Guiraud S, Harriman S et al.. (2020)
2-Arylbenzo[d]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy.
J Med Chem, 63 (14): 7880-7891. [PMID:32551645]
2. Tinsley JM, Fairclough RJ, Storer R, Wilkes FJ, Potter AC, Squire SE, Powell DS, Cozzoli A, Capogrosso RF, Lambert A et al.. (2011)
Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
PLoS ONE, 6 (5): e19189. [PMID:21573153]